Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

Verve Therapeutics has announced the first human proof-of-concept data demonstrating durable reductions in cholesterol for its in vivo base-editing...

By decorating lipid nanoparticles with a cell-specific surface marker, researchers from the University of Pennsylvania were able to edit...

In this clinical trial roundup, we present an overview of the ongoing clinical trials involving base-editing therapeutic candidates. This article...

There are currently four clinical-stage gene-editing candidates in clinical trials for sickle cell disease, which affects millions of people worldwide...

Beam Therapeutics reports dosing of the first patient with BEAM-201, a multiplex-edited allogeneic CAR-T cell candidate developed to treat relapsed or...